Table 2 Data of the studies included in the systematic review and meta-analysis
From: Sustained delivery of chABC improves functional recovery after a spine injury
Refs. | Gender; species; strain; weight or age | Model of injury; location of injury; severity | Numbers: sham; chABC alone; scaffold chABC | Interval time from injury to treatment | chABC concentration | Transplantation type (implant or injection) | Nanoscaffold or hydrogel | FU (week) |
|---|---|---|---|---|---|---|---|---|
Azizi et al. [48] | Male; rat; Wistar; 275 ± 25 g | Contusion; T10; severe | 5; NA; 6 | 1 week | %1 W/W | Injection | PLGA nanoparticles | 8 |
Führmann et al. [53] | Female; rat; SD; 300 g | Compression; T1-2; moderate | n ≥ 9; n ≥ 9; n ≥ 9 | chABC immediately; cell injection 1 week later | 5 μl | Injection | Methylcellulose (XMC) hydrogel | 9 |
Cholas et al. [52] | Female; rat; Lewis; 150–175 | Hemiresection; T8-9; severe | 6; NA; 8 | 0 day | 25 µL of a 10-Units/mL chABC | Implant | EDAC-cross-linked collagen scaffold | 4 |
Pakulska et al. [30] | Female; rat; SD; 200–250 g | Compression; T1-2; moderate | 11; 11; 11 | Immediately after injury | 10 µg | Injection | Methylcellulose hydrogel | 8 |
Xia et al. [54] | Female; rat; Wistar; 200–230 g | Hemitransection; T7–T9; moderate | 6; 6; 6 | During the procedure | NR | Implant | Poly(propylene carbonate) microfibers scaffold | 4 |
Zhang et al. [55] | Female; rat; SD; 200–250 g/2–3 mo | Segmental transversal injury; T10; severe | 8; 8; 8 | After surgery | 0.25 U | Injection | PLGA delayed-release microspheres | 10 |
Pan et al. [56] | Female; rat; Wistar; 250Â g | Transection; T10; severe | 8; 12; 12 | Immediately after injury | 10Â U/mL | Implant | Poly(glycerol sebacate) | 12 |
Ni et al. [57] | Female; rat; Wistar; 200–230 g | Hemisection; T7–T9; severe | 6; 6; 6 | Immediately after injury | %1 W/W | Implant | Poly (propylene carbonate)-chitosan micron fibers scaffold | 4 |
Raspa et al. [33] | Female; rat; SD; 250–275 g | Compression; T9—T10, moderate | 8; 8; 8 | 4 weeks after injury | 0.1 µ/ml | Injection | FAQ self assembled peptide | 6 weeks after injury |